Here is a look at the 2016 performance of the biggest pharmaceutical companies by market cap.
Johnson & Johnson
Market cap: $313.40 billion
Q3 2016 net income: $4.3 billion
Johnson & Johnson is one of the biggest pharmaceutical companies in the world. The company is involved in research and development, as well as manufacturing and sales, for a broad range of products within the healthcare field. Its business is broken down into three main segments: consumer products, pharmaceutical products and medical devices and diagnostics.
Its 2016 Q3 results show sales of $17.8 billion, an increase of 4.2 percent from the same time last year. Domestic sales grew by 6.7 percent, while international sales increased by 1.5 percent. International growth was inhibited by operations in Venezuela.
In a company release, Chairman and CEO Alex Gorsky said the company is “increasingly confident in our pipeline expectation of filing 10 new pharmaceutical products between 2015 and 2019, each with revenue potential over 2 billion.”
“Our third-quarter results reflect the success of our new product launches and the strength of our core businesses, driven by strong growth in our Pharmaceuticals business,” he stated.
Market cap: $196.59 billion
YTD income: $37.5 billion
This Switzerland-based company develops and manufactures prescription drugs and diagnostic products in the areas of oncology, dermatology, transplantations and autoimmune and respiratory diseases.
Roche reported a four percent sales growth for the first three quarters of 2016, earning over $37 billion. Year to date, its pharmaceuticals division has brought in $29 billion, as compared to $27 billion last year. Driving sales in the US were three immunology treatments: Xolair, Esbriet and Actemra/RoActemra. European sales grew as a result of Perjeta, Actemra/RoActemra and MabTheraRituxan.
Market cap: $181.30 billion
Q3 2016 net income: $13 billion
Pfizer is a global pharmaceutical company that develops and produces medicines, including prescription pharmaceuticals, non-prescription self-medications and animal health products. According to its recent financial report, third quarter revenues amounted to 13 billion. The company also lowered the top range of its projected earnings per share, as a result of its decision to discontinue development of bococizumab, a cholesterol medication.
Chairman and CEO Ian Read said the following: “Our business continues to perform well as demonstrated by the quarter’s financial results … we are in a strong position to support the strategic initiatives for each business and will remain opportunistic to business development activity.”
Market cap: $183.34 billion
Q3 2016 net income: 2.9 billion
Novartis produces pharmaceutical and consumer healthcare products for a wide range of issues, including cardiovascular, respiratory and infectious diseases, and vaccines and diagnostics.
Despite losing patent protection for Gleevec, Novartis delivered a strong third quarter in 2016. Net sales came to $12.1 billion, led by growth products like Gilenya and Cosentyx.
“Novartis delivered a solid Q3 despite the Gleevac generic impact in the US, due to the strong performance of our growth products,” said Joseph Jimenez, CEO of Novartis. “We continued to drive innovation, with positive pipeline readouts for LEE011 in advanced breast cancer, BAF312 in SPMS and AMG 334 in episodic migraine. We are continuing to invest for the future, as we manage the Gleevec loss of exclusivity in 2016 and 2017.”
Market cap: $163.17 billion
Q3 2016 net income: $2.1 billion
New Jersey-based Novartis rounds out the five biggest pharmaceutical companies. It delivers global health solutions through the production of vaccines, prescription medicines, biologic therapies and consumer care products.
During Q1 2016 its worldwide sales dropped 1 percent, to $9.3 billion. But Q3 has seen those revenues bounce back: sales amounted to $10.5 billion, an increase of five percent from this time last year.
The company also received positive news about several product candidates, including KEYTRUDA, a cancer treatment. The FDA has approved two supplemental Biologics License Applications for this drug.
“The latest achievements for KEYTRUDA and other recent regulatory approvals across our portfolio show that our innovation strategy is working,” said Kenneth C Frazier, Merck’s CEO and chairman. “We are confident that our focus on the science, along with continued commercial execution, will drive long term results for the company and our shareholders.